BLFS:NSD-BioLife Solutions, Inc (USD)

COMMON STOCK | Medical Instruments & Supplies | NSD

Last Closing Price

USD 28.66

Change

+1.63 (+6.03)%

Market Cap

USD 0.87B

Volume

0.35M

Average Target Price

USD 27.31 (-4.72%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools for the cell and gene therapy industry in North America, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; and liquid nitrogen laboratory freezers, cryogenic equipment, and accessories. The company markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was founded in 1987 and is headquartered in Bothell, Washington.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-29 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ISRG Intuitive Surgical, Inc

-0.23 (-0.03%)

USD81.12B 69.21 52.35
HOLX Hologic, Inc

+0.35 (+0.53%)

USD17.03B 33.52 24.11
MASI Masimo Corporation

+1.55 (+0.67%)

USD12.68B 56.32 40.27
NVCR NovoCure Limited

+0.68 (+0.63%)

USD10.81B 863.67 468.08
XRAY DENTSPLY SIRONA Inc

-0.56 (-1.29%)

USD9.46B 126.19 30.72
RGEN Repligen Corporation

+3.31 (+2.25%)

USD7.73B 245.51 101.96
IRTC iRhythm Technologies, Inc

+4.84 (+2.12%)

USD6.56B N/A N/A
ICUI ICU Medical, Inc

-2.29 (-1.23%)

USD3.88B 47.65 19.23
STAA STAAR Surgical Company

N/A

USD2.58B 336.06 350.34
MMSI Merit Medical Systems, Inc

-0.18 (-0.42%)

USD2.40B 379.20 34.33

ETFs Containing BLFS

Symbol Name Weight Mer Price(Change) Market Cap

Market Performance

  Market Performance vs.
Industry/Classification (Medical Instruments & Supplies)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 77.13% 94% A 89% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 77.13% 94% A 89% B+
Trailing 12 Months  
Capital Gain 75.72% 77% C+ 86% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 75.72% 77% C+ 86% B
Trailing 5 Years  
Capital Gain 1,284.54% 100% A+ 98% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 1,284.54% 100% A+ 98% A+
Average Annual (5 Year Horizon)  
Capital Gain 106.14% N/A N/A 97% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 106.14% N/A N/A 97% A+
Risk Return Profile  
Volatility (Standard Deviation) 133.91% N/A N/A 6% F
Risk Adjusted Return 79.26% N/A N/A 87% B+
Market Capitalization 0.87B 59% F 68% D+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Instruments & Supplies)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 36.25 65% D 28% F
Price/Book Ratio 7.89 22% F 16% F
Price / Cash Flow Ratio 713.11 6% F 0% N/A
EV/EBITDA 37.52 41% F 18% F
Management Effectiveness  
Return on Equity 25.22% 97% A+ 93% A
Return on Invested Capital 3.05% 63% D 54% F
Return on Assets -0.75% 47% F 43% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 4.36 47% F 39% F
Short Percent 5.25% 34% F 38% F
Beta 1.70 22% F 22% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.